Stockscreener 앱 받기
9.07
0.44%
0.04
시장 영업 전:
9.03
-0.04
-0.44%
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
Valuation Update: What is the cash position of LENZ Therapeutics Inc2026 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
LENZ Therapeutics Hits 52-Week Low at $8.86 Amid Ongoing Struggles - Markets Mojo
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum - VisionMonday.com
VIZZ by LENZ Therapeutics: FDA-Approved Once-Daily Eye Drop for Presbyopia Treatment and Market Opportunity 32 - Minichart
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
LENZ Therapeutics 2025 10-K: $19.1M Revenue, $(2.85) EPS - TradingView
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
LENZ: Initial VIZZ launch drove $1.6M sales and $17.5M license revenue, but net loss reached $82.1M - TradingView
VIZZ presbyopia launch propels LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses - Investing.com UK
LENZ Therapeutics Reports Q4 and Full Year 2025 Results; Launches VIZZ Eye Drop for Presbyopia with Strong Prescription Uptake and Expanding Commercial Infrastructure - Minichart
LENZ Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Why Lenz Therapeutics Stock Crashed Today - The Globe and Mail
LENZ Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses By Investing.com - Investing.com India
LENZ: Strong launch momentum, robust cash, and expanding adoption position the product for growth - TradingView
Why Lenz Therapeutics Stock Crashed Today - The Motley Fool
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch - ChartMill
LENZ Therapeutics, Inc. (LENZ) Reports Wider Q4 Loss Than Expected - AlphaStreet
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
LENZ Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
LENZ THERAPEUTICS ($LENZ) Releases Q4 2025 Earnings - Quiver Quantitative
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - The Manila Times
VIZZ launch drives first LENZ (NASDAQ: LENZ) product revenue in 2025 - Stock Titan
LENZ: VIZZ launch drove $1.6M in Q4 sales; net loss rose to $82.1M amid major launch investments - TradingView
LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.9... - Benzinga
LENZ Therapeutics Hits 52-Week Low at USD 11.22 Amidst Declining Performance - Markets Mojo
LENZ Therapeutics Hits 52-Week Low at USD 10.44 Amid Ongoing Struggles - Markets Mojo
LENZ Therapeutics, Inc. (LENZ) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Top Wall Street forecasters revamp LENZ Therapeutics expectations ahead of Q4 earnings - MSN
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
LENZ Therapeutics Inc expected to post a loss of 97 cents a shareEarnings Preview - TradingView
Can LENZ Therapeutics Inc. be the next market leader2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 - The Manila Times
Maker of VIZZ presbyopia eye drop sets March 24 call on 2025 results - Stock Titan
IPO Launch: Is LENZ Therapeutics Inc affected by consumer sentimentMarket Rally & AI Driven Stock Movement Reports - baoquankhu1.vn
693,044 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by First Light Asset Management LLC - MarketBeat
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC's 7th Largest Position - MarketBeat
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
Performance Recap: Can LENZ Therapeutics Inc reach all time highs this year2026 Historical Comparison & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
LENZ Therapeutics Projected to Post Earnings on WednesdayDel Mar Today - National Today
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026 - Meyka
LENZ submits marketing application for presbyopia drug in Europe - Investing.com South Africa
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential By Investing.com - Investing.com Canada
LENZ submits marketing application for presbyopia drug in Europe By Investing.com - Investing.com Australia
LENZ: Rapidly growing prescriber base and strong refill rates highlight successful launch momentum - TradingView
LENZ: Strong launch for a new presbyopia eye drop, with rapid adoption and robust safety profile - TradingView
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential - Investing.com
LENZ Therapeutics Submits Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia - LENZ Therapeutics
New eye drop for age-related blurry vision heads to EU review - Stock Titan
Tyro Capital Management LLC Makes New $4.69 Million Investment in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
Aug Sentiment: Is LENZ Therapeutics Inc a strong candidate for buy and hold2026 Price Momentum & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Market Pulse: Why is LENZ Therapeutics Inc stock going upMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Presbyopia Pipeline 2026: 10+ Companies, 10+ Emerging Therapies, and 3 Key FDA NDA Milestones Driving the Future of Vision Care, analyses DelveInsight - StreetInsider
LENZ: Strong launch momentum for a new presbyopia eye drop, with robust efficacy and market uptake - TradingView
1.82%
자본화:
|
볼륨(24시간):